- The first patient has been dosed in a Phase 1/1b clinical trial evaluating Aptevo Therapeutics' (NASDAQ:APVO) APVO0436, an anti-CD123 x CD3 bispecific antibody, in patients with acute myeloid leukemia (AML) and high-grade myelodysplastic syndrome (MDS). According to ClinicalTrials.gov, the estimated primary completion date is August 2019.
- APV0436 is designed to elicit an immune response against CD123-expressing cancer cells while avoiding cytokine release syndrome associated with cell therapies.
Early-stage study of Aptevo's APV0436 in blood cancers underway
Recommended For You
More Trending News
About APVO Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| APVO | - | - |
| Aptevo Therapeutics Inc. | ||